Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 4 SUPPL., 1999, Pages

  Moss, Denis J ^a,b   Khanna, Rajiv ^a   Sherritt, Martina ^a   Elliott, Suzanne L ^a   Burrows, Scott R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Burkitt's lymphoma; Cytotoxic T cells; Epstein Barr virus; Immunoblastic lymphoma; Immunotherapy; Nasopharyngeal carcinoma

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; BURKITT LYMPHOMA; CANCER PREVENTION; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS INFECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, VIRAL; BURKITT LYMPHOMA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0033179281     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405-31.
2. Thomas JA, Allday MJ, Crawford DH. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res 1991;57:329-80.
3. Su IJ, Hsieh HC. Clinicopathological spectrum of Epstein-Barr virus-associated T-cell malignancies. Leuk Lymphoma 1992;7:47-53.
4. Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990;335:128-30.
5. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1- specific cytotoxic T lymphocytes. Eur J Immunol 1998; 28:451-8.
6. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-8.
7. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91.
8. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
9. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5.
10. Hoffman GJ, Lazarowitz SG, Hayward SD. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA 1980;77:2979-83.
11. Khanna R, Sherritt M, Burrows SR. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 1999; 162:3063-9.
12. Moss DJ, Schmidt C, Elliott S, et al. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv Cancer Res 1996;69:213-45.
13. Scalzo AA, Elliott SL, Cox J, et al. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol 1995;69:1306-9.
14. Thomson SA, Khanna R, Gardner J, et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CDS- cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA 1995;92:5845-9.
15. Ruco LP, Stoppacciaro A, Uccini S, et al. Expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in undifferentiated nasopharyngeal carcinoma (lymphoepithelioma) and in malignant epithelial tumors. Hum Pathol 1994;25:924-8.
16. Karran L, Jones M, Morley G, et al. Expression of a B-cell marker, CD24, on nasopharyngeal carcinoma cells. Int J Cancer 1995;60: 562-6.
17. Zheng YM, Tuppin P, Hubert A, et al. Environmental and dietary risk factors for nasopharyngeal carcinoma - a case-control study in Zangwu County, Guangxi, China. Br J Cancer 1994;69:508-14.
18. Niedobitek G, Young LS, Sam CK, et al. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol 1992;140: 879-87.
19. Kieff E. Epstein-Barr virus: new insights. J Infect Dis 1995;171: 1323-4.
20. Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism. Zentralbl Bakteriol [B] 1978;167:375-90.
21. Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. IAAC Sci Publ 1985;60:249-64.
22. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992;176:169-76.
23. Khanna R, Burrows SR, Argaet V, Moss DJ. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol 1994;6:639-45.
24. Khanna R. Tumour surveillance: missing peptides and MHC molecules. Immunol Cell Biol 1998;76:20-6.
25. Rooney CM, Rowe M, Wallace LE, Rickinson AB. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 1985;317:629-31.
26. Khanna R, Cooper L, Kienzle N, et al. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997;159:5782-5.
27. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DN, Howley PM, eds. Field's virology, 3rd ed. Philadelphia: Lippincott-Raven, 1996:2397-446.